abstract |
The present invention relates to a selective inhibitor of mammalian osteoclast cell activity, processes for its preparation and pharmaceutical compositions comprising the same as well as methods of treatment, where said selective inhibitor is administered to a human or animal patient. Said selective inhibitor has been found to inhibit vacuolar H+-ATPase, such as vacuolar H+-ATPase in osteoclast cells, whereby it is therapeutically efficient against physiological disorders involving bone resorption. In an embodiment of the present invention, said selective inhibitor comprises an imidazopyridine carbonitrile compound with general formula (I). |